피부근염 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 6.9%를 나타내 12억 달러로 성장할 전망입니다. 예측기간 동안의 성장은 자가면역질환 연구에 대한 투자 증가, 새로운 생물학적 요법의 임상검사 증가, 표적 면역억제제의 채용 확대, 생명공학기업 간의 협력관계 확대, 개인화 치료 옵션에 대한 수요 증가로 이어집니다. 예측 기간에 예상되는 주요 동향으로는 표적 면역요법의 진전, mRNA 기반 치료법의 사용 확대, 신규 JAK 억제제의 개발, 인터페론 경로를 표적으로 하는 생물제제의 혁신, 맞춤형 치료 전략의 진전 등이 있습니다.
자가면역 질환의 유병률 증가는 향후 피부근염 치료 시장의 성장을 이끌 것으로 예측됩니다. 자가 면역 질환은 신체의 면역계가 실수로 자신의 건강한 세포와 조직을 공격하여 발생합니다. 이러한 자가면역 질환 증가는 진단 방법의 진보, 인지도의 향상, 환경 요인에 의해 촉진되어 발견률의 향상과 보고 사례 증가에 기여하고 있습니다. 피부근염의 치료는 유해한 면역 반응을 억제하고 환자의 QOL을 향상시키는 표적 치료를 제공함으로써 증가하는 유병률을 관리하는 데 도움이 됩니다. 예를 들어, 2024년 2월 미국 비영리 단체인 Autoimmune Institute는 자가면역 질환이 선진국 인구의 5-10%에 영향을 미친다고 보고했습니다. 그 결과 자가면역질환의 유병률 상승이 피부근염 치료 시장의 확대를 뒷받침하고 있습니다.
피부근염 치료 시장의 주요 기업은 면역계의 과잉 활성에 관여하는 특정 효소를 표적으로 함으로써 염증을 보다 잘 관리하는 JAK 억제제 등의 혁신적인 치료법의 개척에 주력하고 있습니다. 제약 회사 Pfizer는 2022년 6월, 피부근염 환자의 염증과 근력 저하를 억제하는 것을 목적으로 한 경구 JAK1과 TYK2 억제제 브레포시티닙을 발표했습니다. 경구제는 전통적인 주사 요법에 비해 보다 편리한 옵션을 제공하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 피부근염 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 피부근염 치료 시장 : 성장률 분석
- 세계의 피부근염 치료 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 피부근염 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 피부근염 치료 : 전체 시장(TAM)
제6장 시장 세분화
- 세계의 피부근염 치료 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 약리학적 치료
- 면역억제제
- 코르티코스테로이드
- 생물제제
- 물리치료
- 세계의 피부근염 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 정맥
- 피하
- 세계의 피부근염 치료 시장 : 환자 인구 통계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 연령층
- 성별
- 세계의 피부근염 치료 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 온라인 약국
- 소매 약국
- 세계의 피부근염 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 재택치료
- 전문 클리닉
- 기타
- 세계의 피부근염 치료 시장 : 약리학적 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 항말라리아제
- 항바이러스제
- 근육이완제
- 진통제
- 세계의 피부근염 치료 시장 : 면역억제제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 메토트렉세이트
- 아자티오프린
- 마이코페놀레이트모페틸
- 사이클로포스파미드
- 세계의 피부근염 치료 시장 : 코르티코스테로이드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 프레드니손
- 메틸 프레드니솔론
- 하이드로 코르티손
- 덱사메타손
- 세계의 피부근염 치료 시장 : 생물제제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 리툭시맙
- 정맥 내 면역 글로불린(IVIG)
- 토실리주맙
- 아바타셉트
- 세계의 피부근염 치료 시장 : 물리치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 스트레치 운동
- 근력 운동
- 유산소 운동
- 작업요법
제7장 지역별/국가별 분석
- 세계의 피부근염 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 피부근염 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 피부근염 치료 시장 : 경쟁 구도
- 피부근염 치료 시장 : 기업 프로파일
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
제31장 기타 주요 기업 및 혁신 기업
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Amgen Inc.
- Fresenius SE & Co. KGaA
- Bausch Health Companies Inc.
- BIoTest AG
- Galapagos NV
- argenx SE
- Roivant Sciences Ltd.
- Kymera Therapeutics Inc.
- Cabaletta Bio Inc.
- ImmunoForge Inc.
- NovelMed Therapeutics Inc.
- Corbus Pharmaceuticals Holdings Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
- 피부근염 치료 시장(2029년) : 새로운 기회를 제공하는 국가
- 피부근염 치료 시장(2029년) : 새로운 기회를 제공하는 부문
- 피부근염 치료 시장(2029년) : 성장 전략
제36장 부록
KTH
Treatment of dermatomycosis involves antifungal therapies designed to eradicate fungal skin infections. This usually includes the use of topical antifungal creams or ointments like clotrimazole, miconazole, or terbinafine for mild to moderate cases. In more severe or stubborn infections, oral antifungal drugs such as fluconazole or itraconazole may be recommended.
The primary treatment methods for dermatomyositis consist of pharmacological therapies, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments involve the use of medications to manage, relieve, or address symptoms and root causes of the disease. These medications can be administered orally, intravenously, or subcutaneously, with patient groups categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care providers, specialty clinics, and other users.
The dermatomyositis treatment market research report is one of a series of new reports from The Business Research Company that provides dermatomyositis treatment market statistics, including the dermatomyositis treatment industry global market size, regional shares, competitors with the dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historical period is attributed to the rising prevalence of autoimmune diseases, increased awareness of rare inflammatory conditions, global growth in healthcare expenditure, higher diagnosis rates resulting from enhanced screening methods, and growing demand for effective alternatives to corticosteroids.
The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.20 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The projected growth during the forecast period is driven by increasing investments in autoimmune disease research, a rise in clinical trials for new biologic therapies, greater adoption of targeted immunosuppressants, expanding collaborations among biotech companies, and growing demand for personalized treatment options. Key trends expected in the forecast period include progress in targeted immunotherapies, expanded use of mRNA-based therapies, development of new JAK inhibitors, innovations in biologics targeting interferon pathways, and advancements in personalized treatment strategies.
The rising prevalence of autoimmune diseases is anticipated to drive the growth of the dermatomyositis treatment market in the future. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. This increase in autoimmune conditions is fueled by advancements in diagnostic methods, growing awareness, and environmental factors, which contribute to higher detection rates and more reported cases. Treatments for dermatomyositis help manage this growing prevalence by providing targeted therapies that suppress harmful immune responses and enhance patients' quality of life. For example, in February 2024, the Autoimmune Institute, a US-based nonprofit organization, reported that autoimmune diseases affect 5-10% of the population in industrialized countries. As a result, the rising prevalence of autoimmune diseases is propelling the expansion of the dermatomyositis treatment market.
Leading companies in the dermatomyositis treatment market are concentrating on developing innovative therapies, such as JAK inhibitors, to better manage inflammation by targeting specific enzymes involved in immune system overactivity. JAK inhibitors are drugs that block Janus kinase enzymes, helping to decrease the abnormal immune responses responsible for symptoms in autoimmune disorders. For example, in June 2022, Pfizer, a US-based pharmaceutical firm, introduced Brepocitinib, an oral JAK1 and TYK2 inhibitor aimed at reducing inflammation and muscle weakness in dermatomyositis patients. This oral form offers a more convenient option compared to traditional injectable therapies. Brepocitinib addresses the root causes of the disease and has demonstrated potential in enhancing patients' quality of life.
In April 2025, Syneron Bio, a biotechnology firm based in China, partnered with AstraZeneca to jointly develop and commercialize innovative oral peptide therapies targeting chronic and autoimmune diseases. This collaboration combines Syneron Bio's proprietary macrocyclic peptide technology with AstraZeneca's global expertise in drug development. AstraZeneca, headquartered in the UK, is a pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory conditions.
Major players in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., and Corbus Pharmaceuticals Holdings Inc.
North America was the largest region in the dermatomyositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dermatomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dermatomyositis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dermatomyositis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dermatomyositis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomyositis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Pharmacological Treatments; Immunosuppressants; Corticosteroids; Biologics; Physical Therapy
- 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
- 3) By Patient Demographics: Age Group; Gender
- 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
- Subsegments:
- 1) By Pharmacological Treatments: Antimalarials; Antiviral Agents; Muscle Relaxants; Analgesics
- 2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
- 3) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
- 4) By Biologics: Rituximab; Intravenous Immunoglobulin (IVIG); Tocilizumab; Abatacept
- 5)By Physical Therapy: Stretching Exercises; Strength Training; Aerobic Conditioning; Occupational Therapy
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dermatomyositis Treatment Market Characteristics
3. Dermatomyositis Treatment Market Trends And Strategies
4. Dermatomyositis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Dermatomyositis Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dermatomyositis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dermatomyositis Treatment Market Growth Rate Analysis
- 5.4. Global Dermatomyositis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dermatomyositis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dermatomyositis Treatment Total Addressable Market (TAM)
6. Dermatomyositis Treatment Market Segmentation
- 6.1. Global Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmacological Treatments
- Immunosuppressants
- Corticosteroids
- Biologics
- Physical Therapy
- 6.2. Global Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Subcutaneous
- 6.3. Global Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Age Group
- Gender
- 6.4. Global Dermatomyositis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.5. Global Dermatomyositis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
- 6.6. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Pharmacological Treatments,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antimalarials
- Antiviral Agents
- Muscle Relaxants
- Analgesics
- 6.7. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Immunosuppressants,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Methotrexate
- Azathioprine
- Mycophenolate Mofetil
- Cyclophosphamide
- 6.8. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Corticosteroids,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prednisone
- Methylprednisolone
- Hydrocortisone
- Dexamethasone
- 6.9. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Biologics,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rituximab
- Intravenous immunoglobulin (IVIG)
- Tocilizumab
- Abatacept
- 6.10. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Physical Therapy,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Stretching Exercises
- Strength Training
- Aerobic Conditioning
- Occupational Therapy
7. Dermatomyositis Treatment Market Regional And Country Analysis
- 7.1. Global Dermatomyositis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dermatomyositis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dermatomyositis Treatment Market
- 8.1. Asia-Pacific Dermatomyositis Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dermatomyositis Treatment Market
- 9.1. China Dermatomyositis Treatment Market Overview
- 9.2. China Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dermatomyositis Treatment Market
- 10.1. India Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dermatomyositis Treatment Market
- 11.1. Japan Dermatomyositis Treatment Market Overview
- 11.2. Japan Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dermatomyositis Treatment Market
- 12.1. Australia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dermatomyositis Treatment Market
- 13.1. Indonesia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dermatomyositis Treatment Market
- 14.1. South Korea Dermatomyositis Treatment Market Overview
- 14.2. South Korea Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dermatomyositis Treatment Market
- 15.1. Western Europe Dermatomyositis Treatment Market Overview
- 15.2. Western Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dermatomyositis Treatment Market
- 16.1. UK Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dermatomyositis Treatment Market
- 17.1. Germany Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dermatomyositis Treatment Market
- 18.1. France Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dermatomyositis Treatment Market
- 19.1. Italy Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dermatomyositis Treatment Market
- 20.1. Spain Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dermatomyositis Treatment Market
- 21.1. Eastern Europe Dermatomyositis Treatment Market Overview
- 21.2. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dermatomyositis Treatment Market
- 22.1. Russia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dermatomyositis Treatment Market
- 23.1. North America Dermatomyositis Treatment Market Overview
- 23.2. North America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dermatomyositis Treatment Market
- 24.1. USA Dermatomyositis Treatment Market Overview
- 24.2. USA Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dermatomyositis Treatment Market
- 25.1. Canada Dermatomyositis Treatment Market Overview
- 25.2. Canada Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dermatomyositis Treatment Market
- 26.1. South America Dermatomyositis Treatment Market Overview
- 26.2. South America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dermatomyositis Treatment Market
- 27.1. Brazil Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dermatomyositis Treatment Market
- 28.1. Middle East Dermatomyositis Treatment Market Overview
- 28.2. Middle East Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dermatomyositis Treatment Market
- 29.1. Africa Dermatomyositis Treatment Market Overview
- 29.2. Africa Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dermatomyositis Treatment Market Competitive Landscape And Company Profiles
- 30.1. Dermatomyositis Treatment Market Competitive Landscape
- 30.2. Dermatomyositis Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Dermatomyositis Treatment Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. GlaxoSmithKline plc
- 31.3. Eli Lilly and Company
- 31.4. Amgen Inc.
- 31.5. Fresenius SE & Co. KGaA
- 31.6. Bausch Health Companies Inc.
- 31.7. Biotest AG
- 31.8. Galapagos NV
- 31.9. argenx SE
- 31.10. Roivant Sciences Ltd.
- 31.11. Kymera Therapeutics Inc.
- 31.12. Cabaletta Bio Inc.
- 31.13. ImmunoForge Inc.
- 31.14. NovelMed Therapeutics Inc.
- 31.15. Corbus Pharmaceuticals Holdings Inc.
32. Global Dermatomyositis Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dermatomyositis Treatment Market
34. Recent Developments In The Dermatomyositis Treatment Market
35. Dermatomyositis Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Dermatomyositis Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dermatomyositis Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dermatomyositis Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
